~~<i id='104EE233A3'><strike id='104EE233A3'><tt id='104EE233A3'><pre id='104EE233A3'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

comprehensive

author：comprehensive 2025-10-01 04:10:54 - browse：5952

Calling Bullshit course University of Washington — Screenshot via callingbullshit.org

Tired of alternative facts, fake news, and breathless hyperbole, two professors at the University of Washington are trying to strike a blow for science.

Their weapon? A new course: “Calling Bullshit In the Age of Big Data.”

The class website and colorful syllabus went online last month and almost instantly went viral.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Steward Health Care Massachusetts hospitals face fiscal disaster

explore

hotspot

knowledge

leisure time

GermantroopsandartilleryparadethroughthestreetsofVienna,afterHitlerhadenteredthecity,March1938.Londo

WSS

Readout Newsletter: Merck, J&J, and long Covid

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Research misconduct: Proposed new rules face resistance

RaDonda Vaught links Vanderbilt hospital issues to patient death

New brain studies show LSD's effects on the brain in full color

NIH director takes cautious approach to Biden drug pricing priority

hotspot

comprehensive

explore

Medical records are filled with copy

How to save health care price transparency rules

Heart attack and stroke risk calculators need revising

Biotech venture capitalists face new demands from investors

Walensky prepares to leave CDC — and Congress — behind

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Walensky prepares to leave CDC — and Congress — behind

Amid AI frenzy, a top HHS official's quest to create safeguards

Supreme Court strikes down use of affirmative action

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

hotspot

Dewpoint Therapeutics lays off staff after losing partnerships

Ebola: Gilead Sciences antiviral shows promise as new treatment

Think you might have Covid

EU regulator recommends expanding Mounjaro approval to obesity

Prior authorization will have to move faster under new Biden rule

How digital therapeutics firms are pivoting after Pear's bankruptcy

hotspot

knowledge

knowledge

leisure time